Feline Infectious Peritonitis, (FIP) is no longer a death sentence for cats, thanks to GS-441524.
A virus known as feline infectious peritonitis, or FIP, is thought to afflict 1-2 percent of all cats worldwide each year. If left untreated, FIP is expected to have an approximately 96% fatality rate.
However, FIP does no longer need to be a death sentence for cats. The discovery of the usage of GS-441524 has transformed the treatment of FIP, according to Dr. Niels Pedersen and his team of researchers at the University of California Davis. An illness that was previously lethal is now easily treated.
Throughout his fifty-year career, Dr. Niels Pedersen, an emeritus professor at UC Davis, focused on researching FIP and finding a treatment.
Dr. Pedersen informs Eyewitness News that FIP claims the lives of one percent of cats. “This is a pandemic for cats.”
A medication known as GS-441524, or GS for short, was the cure that Pedersen and his team at UC Davis discovered. It prevents the virus from multiplying.
Both the wet and dry types of FIP have shown excellent success rates when treated with GS-441524, according to clinical trials and anecdotal data. in particular, FIP dry form with skeletal (legs, brain) or ocular (eyes) neurology.
At MedicaPharma we are bringing GS-441524 within the reach and affordability of veterinary professionals and cat owners, enabling them to use it to save the lives of cats.
Download GMP-Certified API Product List
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations. Click here to download our complete API product list.
Get your requested raw materials quotation
Table of Contents
A 92% success rate in curing FIP
The most effective FIP treatment strategy is GS-441524, generally known as just GS.
It has been shown to be 92% successful when the correct treatment protocols are followed. It produces quick results and has no unfavourable side effects. GS-441524 is a FIP antiviral molecule that has shown efficacy in treating feline coronavirus, irrespective of the severity and duration of symptoms.
Several additional reports demonstrate the therapeutic efficacy of GS-441524 administered orally or by injection for the treatment of FIP. When GS-441524 is administered subcutaneously to cats with spontaneously occurring FIP, survival rates increase to 77% after six months. This does not apply to cats with ocular or severe neurologic forms, where medication penetration into the bloodstream is unknown and blood-brain and blood-eye is uncertain. 1, 2, and 2.
Get your requested raw materials quotation
A safe treatment
GS-441524 has been proven to be a safe and successful treatment for the condition in cats, with the majority of clinical trials taking place in Australia and the UK.
The treatment with GS-441524 has remarkably few systemic side effects. In certain cats, it may result in mild kidney damage; however, overt renal illness does not develop from this. A few cats have experienced systemic medication reactions of the vasculitis variety, which are sometimes mistaken for injection site reactions.
Available as an injectable drug and oral formulation
Initially developed as an injectable drug, the transition to an oral formulation represents an important step in making GS-441524 a more feasible treatment modality for most cat owners. Contact us if you would like more information in regards to the difference between injections and oral tablets to determine what product is most suitable for your needs.
GS-441524 is now FDA-approved in several countries
For a number of years, many understandably frantic owners of FIP-infected cats in the United States sought this substance through unregulated and frequently untrustworthy black-market sources because it was not previously FDA-approved. This announcement offers a significant glimmer of hope in the treatment of a previously incurable and devastating feline disease, along with the FDA’s Centre for Veterinary Medicine’s (CVM) notification to veterinarians that compounded GS-441524 falls under Guidance for Industry #256 and is permitted to be compounded and lawfully prescribed.
Produced in a GMP facility
Today, the market is flooded with GS-441524. As a result, the important thing when buying the product is to ensure the GS-441524 is of the highest quality since this will directly affect the result of the treatment.
At MedicaPharma we are committed to using only the finest materials and ingredients in our products, carefully avoiding any substances that could trigger allergic reactions in your cat. Our GS-441524 is therefore produced in a GMP facility. Several veterinary institutes in Europe use our raw materials with very good results. If you would like more information, references are available upon request.
Get a Fast and Easy GMP-Certified API Quote
Focus on your compounding pharmacy business and let MedicaPharma take care of your APIs. Obtaining a quote is easy
